Leqvio FDA Approval
Guidelines recognize evidence of link between lower LDL-C and
improved outcomes³
AHA/ACC (2018)1
Clinical ASCVD
LDL-C reduction
by ≥50%
Very high CVD risk
LDL-C reduction
to <70 mg/dL
(1.8 mmol/L)
ESC/EAS (2021)²
High CV risk
LDL-C reduction
to <70 mg/dL
(1.8 mmol/L)
and
LDL-C reduction
by ≥50%
In the real world, consistent and sustained LDL-C lowering is in many
cases not achieved due to adherence, access, and affordability challenges
Very high CV risk
LDL-C reduction
to <55 mg/dL
(1.4 mmol/L)
and
LDL-C reduction
by ≥50%
ASCVD Atherosclerotic
3. The effect of
LDL-C - Low Density Lipoprotein Cholesterol. AHA American Heart Association. ACC American College of Cardiology. ESC European Society of Cardiology. EAS - European Atherosclerosis Society.
Cardiovascular Disease. CVD Cardiovascular Disease. CV-Cardiovascular. 1. Grundy SM, et al. J Am Coll Cardiol. 2019;73(24):3237-3241. 2. Visseren FLJ et al. Eur Heart J. 2021; Sep 7; 42(34):3227-3337.
LeqvioⓇ on cardiovascular morbidity and mortality is currently being studied in the ongoing Phase III ORION-4 trial.
11 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation
NOVARTIS | Reimagining MedicineView entire presentation